CAR-T细胞疗法治疗高度侵袭性B细胞淋巴瘤:新兴生物学与临床见解
本文综述了靶向CD19的自体嵌合抗原受体(CAR)T细胞疗法在复发/难治性弥漫性大B细胞淋巴瘤(DLBCL)中的高效性及监管批准,并指出近期报告提示该策略对高级别B细胞淋巴瘤有效;文中讨论了这些高度侵袭性亚型的生物学基础及其与DLBCL的重叠,以及肿瘤细胞特异性和微环境因素如何影响对该疗法的易感性。
要点
- 靶向CD19的自体CAR-T细胞在复发/难治性DLBCL中高度有效,已获监管批准。
- 近期报告提示CAR-T细胞疗法对高级别B细胞淋巴瘤是有效策略。
- 肿瘤细胞特异性和微环境因素可能影响高度侵袭性亚型对CAR-T的易感性。
核心结论
- 靶向CD19的自体CAR-T细胞疗法在复发/难治性DLBCL中高度有效并获监管批准,近期报告提示其对高级别B细胞淋巴瘤亦为有效策略。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 靶向B细胞CD19抗原的自体CAR-T细胞 strategy 在复发/难治性DLBCL患者中高度有效,体现于近期监管批准。
- 近期报告提示该策略对高级别B细胞淋巴瘤有效。
- 这些高度侵袭性亚型的生物学基础及其与DLBCL的重叠仍是深入研究的领域。
- 肿瘤细胞特异性和微环境因素如何影响这些高度侵袭性亚型对该方法的易感性值得思考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recently, significant progress has been made in identifying novel therapies, beyond conventional immunochemotherapy strategies, with efficacy in B-cell lymphomas. One such approach involves targeting the CD19 antigen on B cells with autologous-derived chimeric antigen receptor (CAR) cells. This strategy is highly effective in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), as evidenced by recent regulatory approvals. Recent reports suggest that this is an effective strategy for high-grade B-cell lymphoma. The biological underpinnings of these entities and how they overlap with each other and DLBCL continue to be areas of intense investigation. Therefore, as more experience with CAR T-cell approaches is examined, it is interesting to consider how both tumor cell-specific and microenvironmental factors that define these highly aggressive subsets influence susceptibility to this approach.
引用
- Ali A, Goy A, Dunleavy K, et al. CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights. Blood. 2022. PMID: 35560330. doi:10.1182/blood.2022016226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。